The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
26
Tablets for oral administration.
htTKV on MRI Over Time
Time frame: Baseline up to End of Study (Week 52)
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 54
Maximum Observed Plasma Concentration (Cmax) of VX-407
Time frame: From Day 1 up to Week 52
Area Under the Concentration Versus Time Curve (AUC) of VX-407
Time frame: From Day 1 up to Week 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alabama Kidney Research
Alabaster, Alabama, United States
UAB Nephrology Research at CH19
Birmingham, Alabama, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
UCSF Clinical Research Center at Parnassus
San Francisco, California, United States
Nephrology & Hypertension Associates, PC
Middlebury, Connecticut, United States
Yale University - Yale Nephrology Clinical Research Clinic
New Haven, Connecticut, United States
Mayo Clinic - Jacksonville
Jacksonville, Florida, United States
Emory School of Medicine - Renal Division
Atlanta, Georgia, United States
Renal Associates
Columbus, Georgia, United States
UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology
Chicago, Illinois, United States
...and 33 more locations